cp-506
Small moleculeexperimental
Clinical trial activity
1 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 31, 2021 (NCT04954599)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- DNACROSS-LINKING AGENT
DNA cross-linking agent
Chemistry & pharmacology
Loading structure…
SMILES
CCN1CCN(C(=O)c2cc(N(CCBr)CCOS(C)(=O)=O)c(S(C)(=O)=O)cc2[N+](=O)[O-])CC1- Mol. weight
- 585.5 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5417217 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04954599 | Phase 1/Phase 2 (Phase 2) | Oct 31, 2021 | Erasmus University Rotterdam, Free University of Brussels, Maastricht University, Netherlands Cancer Institute |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Erasmus University Rotterdam | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Free University of Brussels | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Maastricht University | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Netherlands Cancer Institute | Academic/Hospital | 1 | 0 | 1 | 2021 |
4 organizations
Page 1 / 1